2026 Q1 -tulosraportti
87 päivää sitten
‧1 t 2 min
7,95 DKK/osake
Viimeisin osinko
3,82%Tuotto/v
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 5.8. | 4 päivää |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 5.11.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·1 t sittenA bunch of weaklings like you who get so scared just because Novo falls almost 10 % Uhhhh oh, then we better sell... You are ridiculous and fool yourselves This one will be past 400 kr by the turn of the year It will be big 🚀🚀🚀🚀
I don't understand your arguments? It's not us small investors here on nordnet that can influence the price so strongly at all.! So the really big boys are trading. pension funds, funds, hedge funds), who trade millions of kroner at a time.
·1 t sittenThe rats really came out of the woodwork, leading up to the quarterly report… It's striking how people unilaterally wish Novo on its knees, solely due to their own short interests. Do you have no understanding that this affects real human lives, who risk layoffs, because of you?
·1 t sittenNovo falls sharply on bad news and hardly rises on good news. If the ziltivekimab phase 3 study had succeeded, it would at most have led to an increase of 1-2%. Now, instead, it leads to a fall of 8%. The reason analysts are negative on Novo is that growth is now negative and is not expected to improve next year. The reason growth has decreased is Trump's price reductions and patent expiry on semaglutide in Canada and in the East. It is normal that the patent period in Canada and in the East is not as long as in the USA and Europe. The semaglutide patent expires in 2031/32 in the USA and Europe. Likewise, there has been increasing competition from Eli Lilly, and other competitors are also expected to lower prices in the obesity area. If you go under the tab "About the company", Novo's P/E is now 11.17. This figure is calculated by taking the current share price divided by normalized earnings per share for 2025. That is, earnings without one-off income and one-off expenses. If you click on the 4 bars, you can see that P/E 2026 = 14.26 and P/E 2027 = 14.38 and P/E 2028 = 13.26. If you want profit per share, you can see why the Novo share price is not rising. EPS 2026 = 21.49 and EPS 2027 = 21.32 and EPS 2028 = 23.12. Here you can see that earnings per share are expected to fall in 2027 and earnings in 2028 are largely the same as in 2025. If you are to buy Novo, you must believe that growth will return. That is what Mike Doustdar must prove on Wednesday, that growth is back at Novo. Here is the Wegovy pill, where you have the SNAC technology that provides a pill with greater weight loss and fewer side effects than the flopdayo pill. Foundayo is so far a flop as the weight loss is less and there are liver problems. Likewise, the pill can conflict with other medication one takes, e.g., birth control pills that don't work. The problem for Novo with the Wegovy pill is that it requires a lot of Semaglutide, where production capacity is a problem. The same problem exists with CagriSema, which also requires a lot of production capacity. CagriSema has caused Novo's share price to collapse several times, where the desired weight loss of 25% was not achieved, but instead 23%. However, one must expect that if CagriSema is tested with 7.2 mg semaglutide, the weight loss will be 25-26%. CagriSema is expected to be approved this year, and one must hope that CagriSema surprises as much as the Wegovy pill. Amycretin is the next product Novo will launch, and it is expected to be approved in 2028/29. It is easier to produce and also comes in a pill version. Novo's growth must come from new products and the SNAC technology, which makes it impossible to copy the Wegovy pill. Growth must return, otherwise the share price will not rise.
Thanks for the AI post The typical investor today spreads one's AI answers instead of real thoughts which the forum is for- ·4 t sittenI've been thinking about something. Is it just me, or is it perhaps us as shareholders who have helped talk up the Novo story, because we so much want to believe in it? I'm thinking about the last year or so. I find it hard to recall a big positive piece of news from Novo that truly changed the case. It's not criticism – I'm just curious if I'm overlooking something. What do you think?
I think it is a good company and I am long-term oriented with dividends in mind. They are trying to develop new products that we can benefit from, some succeed but many do not. They have a good foundation to build upon with good products. It is natural that the share price will go up and down when there is potential for good earnings. 
·4 t sittenAm I the only one who thinks this way? I know that a listed company must disclose price-sensitive information as soon as it is ready. But a Phase 3 study is not analyzed from one minute to the next. Could Novo still have chosen to publish the Phase 3 result now, so that it wouldn't overshadow the Q2 report on Wednesday? If the report is good, it might have been a deliberate way to separate the two news items. What do you think?
I believe it was a conscious choice from Novo's side to publish data from the Zeus study yesterday. As you write, to separate things. I expect and hope for strong financial results on Wednesday 🤞🤞
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
87 päivää sitten
‧1 t 2 min
7,95 DKK/osake
Viimeisin osinko
3,82%Tuotto/v
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·1 t sittenA bunch of weaklings like you who get so scared just because Novo falls almost 10 % Uhhhh oh, then we better sell... You are ridiculous and fool yourselves This one will be past 400 kr by the turn of the year It will be big 🚀🚀🚀🚀I don't understand your arguments? It's not us small investors here on nordnet that can influence the price so strongly at all.! So the really big boys are trading. pension funds, funds, hedge funds), who trade millions of kroner at a time.
- ·1 t sittenThe rats really came out of the woodwork, leading up to the quarterly report… It's striking how people unilaterally wish Novo on its knees, solely due to their own short interests. Do you have no understanding that this affects real human lives, who risk layoffs, because of you?
- ·1 t sittenNovo falls sharply on bad news and hardly rises on good news. If the ziltivekimab phase 3 study had succeeded, it would at most have led to an increase of 1-2%. Now, instead, it leads to a fall of 8%. The reason analysts are negative on Novo is that growth is now negative and is not expected to improve next year. The reason growth has decreased is Trump's price reductions and patent expiry on semaglutide in Canada and in the East. It is normal that the patent period in Canada and in the East is not as long as in the USA and Europe. The semaglutide patent expires in 2031/32 in the USA and Europe. Likewise, there has been increasing competition from Eli Lilly, and other competitors are also expected to lower prices in the obesity area. If you go under the tab "About the company", Novo's P/E is now 11.17. This figure is calculated by taking the current share price divided by normalized earnings per share for 2025. That is, earnings without one-off income and one-off expenses. If you click on the 4 bars, you can see that P/E 2026 = 14.26 and P/E 2027 = 14.38 and P/E 2028 = 13.26. If you want profit per share, you can see why the Novo share price is not rising. EPS 2026 = 21.49 and EPS 2027 = 21.32 and EPS 2028 = 23.12. Here you can see that earnings per share are expected to fall in 2027 and earnings in 2028 are largely the same as in 2025. If you are to buy Novo, you must believe that growth will return. That is what Mike Doustdar must prove on Wednesday, that growth is back at Novo. Here is the Wegovy pill, where you have the SNAC technology that provides a pill with greater weight loss and fewer side effects than the flopdayo pill. Foundayo is so far a flop as the weight loss is less and there are liver problems. Likewise, the pill can conflict with other medication one takes, e.g., birth control pills that don't work. The problem for Novo with the Wegovy pill is that it requires a lot of Semaglutide, where production capacity is a problem. The same problem exists with CagriSema, which also requires a lot of production capacity. CagriSema has caused Novo's share price to collapse several times, where the desired weight loss of 25% was not achieved, but instead 23%. However, one must expect that if CagriSema is tested with 7.2 mg semaglutide, the weight loss will be 25-26%. CagriSema is expected to be approved this year, and one must hope that CagriSema surprises as much as the Wegovy pill. Amycretin is the next product Novo will launch, and it is expected to be approved in 2028/29. It is easier to produce and also comes in a pill version. Novo's growth must come from new products and the SNAC technology, which makes it impossible to copy the Wegovy pill. Growth must return, otherwise the share price will not rise.Thanks for the AI post The typical investor today spreads one's AI answers instead of real thoughts which the forum is for
- ·4 t sittenI've been thinking about something. Is it just me, or is it perhaps us as shareholders who have helped talk up the Novo story, because we so much want to believe in it? I'm thinking about the last year or so. I find it hard to recall a big positive piece of news from Novo that truly changed the case. It's not criticism – I'm just curious if I'm overlooking something. What do you think?I think it is a good company and I am long-term oriented with dividends in mind. They are trying to develop new products that we can benefit from, some succeed but many do not. They have a good foundation to build upon with good products. It is natural that the share price will go up and down when there is potential for good earnings.
- ·4 t sittenAm I the only one who thinks this way? I know that a listed company must disclose price-sensitive information as soon as it is ready. But a Phase 3 study is not analyzed from one minute to the next. Could Novo still have chosen to publish the Phase 3 result now, so that it wouldn't overshadow the Q2 report on Wednesday? If the report is good, it might have been a deliberate way to separate the two news items. What do you think?I believe it was a conscious choice from Novo's side to publish data from the Zeus study yesterday. As you write, to separate things. I expect and hope for strong financial results on Wednesday 🤞🤞
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 5.8. | 4 päivää |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 5.11.2025 |
2026 Q1 -tulosraportti
87 päivää sitten
‧1 t 2 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 5.8. | 4 päivää |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 5.11.2025 |
7,95 DKK/osake
Viimeisin osinko
3,82%Tuotto/v
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·1 t sittenA bunch of weaklings like you who get so scared just because Novo falls almost 10 % Uhhhh oh, then we better sell... You are ridiculous and fool yourselves This one will be past 400 kr by the turn of the year It will be big 🚀🚀🚀🚀I don't understand your arguments? It's not us small investors here on nordnet that can influence the price so strongly at all.! So the really big boys are trading. pension funds, funds, hedge funds), who trade millions of kroner at a time.
- ·1 t sittenThe rats really came out of the woodwork, leading up to the quarterly report… It's striking how people unilaterally wish Novo on its knees, solely due to their own short interests. Do you have no understanding that this affects real human lives, who risk layoffs, because of you?
- ·1 t sittenNovo falls sharply on bad news and hardly rises on good news. If the ziltivekimab phase 3 study had succeeded, it would at most have led to an increase of 1-2%. Now, instead, it leads to a fall of 8%. The reason analysts are negative on Novo is that growth is now negative and is not expected to improve next year. The reason growth has decreased is Trump's price reductions and patent expiry on semaglutide in Canada and in the East. It is normal that the patent period in Canada and in the East is not as long as in the USA and Europe. The semaglutide patent expires in 2031/32 in the USA and Europe. Likewise, there has been increasing competition from Eli Lilly, and other competitors are also expected to lower prices in the obesity area. If you go under the tab "About the company", Novo's P/E is now 11.17. This figure is calculated by taking the current share price divided by normalized earnings per share for 2025. That is, earnings without one-off income and one-off expenses. If you click on the 4 bars, you can see that P/E 2026 = 14.26 and P/E 2027 = 14.38 and P/E 2028 = 13.26. If you want profit per share, you can see why the Novo share price is not rising. EPS 2026 = 21.49 and EPS 2027 = 21.32 and EPS 2028 = 23.12. Here you can see that earnings per share are expected to fall in 2027 and earnings in 2028 are largely the same as in 2025. If you are to buy Novo, you must believe that growth will return. That is what Mike Doustdar must prove on Wednesday, that growth is back at Novo. Here is the Wegovy pill, where you have the SNAC technology that provides a pill with greater weight loss and fewer side effects than the flopdayo pill. Foundayo is so far a flop as the weight loss is less and there are liver problems. Likewise, the pill can conflict with other medication one takes, e.g., birth control pills that don't work. The problem for Novo with the Wegovy pill is that it requires a lot of Semaglutide, where production capacity is a problem. The same problem exists with CagriSema, which also requires a lot of production capacity. CagriSema has caused Novo's share price to collapse several times, where the desired weight loss of 25% was not achieved, but instead 23%. However, one must expect that if CagriSema is tested with 7.2 mg semaglutide, the weight loss will be 25-26%. CagriSema is expected to be approved this year, and one must hope that CagriSema surprises as much as the Wegovy pill. Amycretin is the next product Novo will launch, and it is expected to be approved in 2028/29. It is easier to produce and also comes in a pill version. Novo's growth must come from new products and the SNAC technology, which makes it impossible to copy the Wegovy pill. Growth must return, otherwise the share price will not rise.Thanks for the AI post The typical investor today spreads one's AI answers instead of real thoughts which the forum is for
- ·4 t sittenI've been thinking about something. Is it just me, or is it perhaps us as shareholders who have helped talk up the Novo story, because we so much want to believe in it? I'm thinking about the last year or so. I find it hard to recall a big positive piece of news from Novo that truly changed the case. It's not criticism – I'm just curious if I'm overlooking something. What do you think?I think it is a good company and I am long-term oriented with dividends in mind. They are trying to develop new products that we can benefit from, some succeed but many do not. They have a good foundation to build upon with good products. It is natural that the share price will go up and down when there is potential for good earnings.
- ·4 t sittenAm I the only one who thinks this way? I know that a listed company must disclose price-sensitive information as soon as it is ready. But a Phase 3 study is not analyzed from one minute to the next. Could Novo still have chosen to publish the Phase 3 result now, so that it wouldn't overshadow the Q2 report on Wednesday? If the report is good, it might have been a deliberate way to separate the two news items. What do you think?I believe it was a conscious choice from Novo's side to publish data from the Zeus study yesterday. As you write, to separate things. I expect and hope for strong financial results on Wednesday 🤞🤞
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt